Anal human papillomavirus among men who have sex with men in three metropolitan cities in southern China: implications for HPV vaccination

IntroductionMen who have sex with men (MSM), especially those infected with human immunodeficiency virus (HIV), are at disproportionate risk for human papillomavirus (HPV) infection. Data about anal HPV prevalence among MSM in southern China are limited.MethodsMSM were recruited between January 1 and August 31, 2017 in three metropolitan cities: Guangzhou, Shenzhen and Wuxi. A self-completed tablet-based questionnaire was used to collect information about socio-demographic/sexual behavioral characteristics, history of sexually transmitted infections (STIs) and recreational drug use. An anal brush was used to collect exfoliated cells for HPV DNA testing and genotyping, and a blood sample was taken for HIV testing. Penile/anal warts were checked by a clinician.ResultsA total of 536 MSM were enrolled, including 39 HIV-positive and 497 HIV-negative individuals. Compared with HIV-negative MSM, prevalence of any HPV genotype (79.5% vs 46.7%), any high-risk genotype (64.1% vs 36.6%) and any nonavalent vaccine-preventable genotype (53.9% vs 31.6%) was significantly higher in HIV-positive MSM, with all P < 0.01. HIV infection (adjusted odds ratio [AOR], 4.28; 95% confidence interval [CI], 1.87–9.80), using recreational drugs (AOR, 1.87; 95% CI, 1.22–2.87), having ≥ 3 years of sexual experience (AOR, 1.52; 95% CI, 1.01–2.28), having ≥ 6 lifetime male partners (AOR, 1.92; 95% CI, 1.29–2.86), and engaging receptive anal intercourse (AOR, 2.30; 95% CI, 1.48–3.57) were associated with higher anal HPV prevalence. Any HPV prevalence increased with age, from 24.5% at < 20 years to 55.8% at ≥ 40 years.ConclusionsAnal HPV prevalence was high among MSM in southern China, significantly associated with HIV status and sexual experience. HPV prevalence increased with age among MSM. A targeted HPV vaccination program for teenage MSM might be necessary. Our findings will inform targeted HPV modelling among MSM in China.     

台州市男男性行为者HIV感染和新型毒品使用与人乳头瘤病毒感染相关分析

目的:分析台州市男男性行为者（MSM）中HIV阴性者和HIV感染者中新型毒品使用与肛管人乳头瘤病毒（HPV）感染的相关性。方法:采用横断面调查方法,分别于2016年8月至2017年10月在台州市4个区（县）CDC自愿咨询检测门诊采用方便抽样招募HIV阴性MSM、2016年8月至2019年6月招募台州市随访管理的HIV感...     

High-risk sexual behavior by HIV-positive men who have sex with men--16 sites, United States, 2000-2002

The majority of persons living with human immunodeficiency virus (HIV) in the United States are men who have sex with men (MSM). High-risk sexual behavior by HIV-positive MSM exposes sex partners to HIV. The risk for transmitting HIV from an infected partner to an uninfected partner through unprotected insertive anal intercourse (UIAI) is greater than the risk for transmission through receptive anal intercourse or oral sex. Differences in sexual risk behavior might be associated with the perceived HIV serostatus of the partner (i.e., HIV positive, HIV negative, or unknown serostatus), as well as with the sex partner type (i.e., steady or nonsteady). During May 2000-December 2002, HIV-positive MSM were interviewed in a behavioral surveillance survey at surveillance sites in 16 states. This report describes insertive anal intercourse practices reported by these MSM; findings indicated that a large percentage of HIV-positive MSM were sexually abstinent, practiced safer sexual behavior by having protected insertive anal intercourse, or had UIAI with an HIV-positive partner. However, a small percentage of HIV-positive MSM reported UIAI with partners who were HIV negative or whose serostatus was unknown; for this group, more intensive and comprehensive HIV-prevention efforts are needed to eliminate this risk behavior.     

Anal human papillomavirus infections in young unvaccinated men who have sex with men attending a sexual health clinic for HPV vaccination in Melbourne,Australia

The Victorian Government introduced a time-limited quadrivalent human papillomavirus (HPV) vaccination catch-up program targeting gay and bisexual men who have sex with men (MSM) aged up to 26 years in 2017. As of 2017, men aged ≥20 years were not eligible for the school-based HPV vaccination program. This study examined the prevalence of anal HPV among 496 MSM aged 20–26 years before they received the first dose of the HPV vaccine at the Melbourne Sexual Health Centre, Australia. More than half (56.5%) had any high-risk HPV genotypes detected in the anus. Almost half (43.1%) had at least one quadrivalent HPV vaccine-preventable genotype (6, 11, 16 or 18) and one-fifth (21.0%) had HPV 16 detected in the anus. These findings suggest that a targeted catch-up HPV vaccination program for MSM is still beneficial to protect against high-risk HPV genotypes associated with anal cancer, as well as low-risk HPV genotypes.     

Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective

BackgroundWe investigated the effectiveness and cost-effectiveness of a targeted human papillomavirus (HPV) vaccination program for young (15–26) men who have sex with men (MSM).MethodsWe developed a compartmental model to project HPV epidemic trajectories in MSM for three vaccination scenarios: a boys program, a targeted program for young MSM only and the combination of the two over 2017–2036. We assessed the gain in quality-adjusted-life-years (QALY) in 190,000 Australian MSM.ResultsA targeted program for young MSM only that achieved 20% coverage per year, without a boys program, will prevent 49,283 (31,253–71,500) cases of anogenital warts, 191 (88–319) person-years living with anal cancer through 2017–2036 but will only stablise anal cancer incidence. In contrast, a boys program will prevent 82,056 (52,100–117,164) cases of anogenital warts, 447 (204–725) person-years living with anal cancers through 2017–2036 and see major declines in anal cancer. This can reduce 90% low- and high-risk HPV in young MSM by 2024 and 2032, respectively, but will require vaccinating ≥84% of boys. Adding a targeted program for young MSM to an existing boys program would prevent an additional 14,912 (8479–21,803) anogenital wart and 91 (42–152) person-years living with anal cancer. In combination with a boys’ program, a catch-up program for young MSM will cost an additional $AUD 6788 ($4628–11,989) per QALY gained, but delaying its implementation reduced its cost-effectiveness.ConclusionsA boys program that achieved coverage of about 84% will result in a 90% reduction in HPV. A targeted program for young MSM is cost-effective if timely implemented.     

How very young men who have sex with men view vaccination against human papillomavirus

Background

HPV vaccination of men who have sex with men (MSM) prior to the commencement of sexual activity would have the maximum impact on preventing HPV and anal cancer in this population. However, knowledge and attitudes towards HPV vaccination among very young MSM have not been previously studied.

Methods

Two hundred MSM aged 16 to 20 were recruited via community and other sources. Participants were asked about their knowledge and attitudes towards HPV and HPV vaccination.

Results

Most (80%, 95% confidence interval (CI) 72.2–87.2%) men were not willing to purchase the vaccine because of its cost (AUD$450). However, if the vaccine was offered to MSM free of charge, 86% (95% CI: 80–90%) reported they would be willing to disclose their sexuality to a health care provider in order to obtain the vaccine. Over half (54%, 95%: 47–61%) of men would only be willing to disclose their sexuality to receive the HPV vaccine after their first experience of anal intercourse. The age at first insertive anal intercourse and the age at first receptive anal intercourse were 0.21 (IQR: −2.5 to 3.2) and 0.17 (IQR: −2.9 to 2.7) years earlier than the age that men would be willing to disclose their sexuality to receive the HPV vaccine, respectively. Willingness to receive the vaccine at a younger age was associated with younger age at first insertive anal intercourse.

Conclusion

Overall, very young MSM expressed high acceptance of HPV vaccination. Early, opportunistic vaccination of very young MSM may be feasible in settings where very young MSM have not been vaccinated through universal programs targeting school aged males. However, given HPV infections occur early on, the effectiveness of this approach will be less than vaccination targeting school aged boys.     

我国男男性行为人群中人乳头瘤病毒疫苗接种的需求与建议

MSM是HPV感染与相关疾病发生的高危人群,四价和九价HPV疫苗能够为MSM提供有效的保护。本文综述了为MSM提供HPV疫苗接种的重要性,综合了关于MSM接种HPV疫苗的依据并提出建议:我国应加快HPV疫苗在男性中使用的适应症研究及审批;尽快为HIV阳性的MSM接种HPV疫苗;优先为 ≤ 26岁MSM接种HPV疫苗;在HPV疫苗资源充分的情况下,为>26岁的MSM进行补接种或机会性接种。采用这种接种策略能够为MSM提供保护,控制性病和艾滋病的传播。     

Risk behaviours and HIV infection among men having sexual relations with men: baseline characteristics of participants in the Omega Cohort Study, Montreal, Quebec, Canada

OBJECTIVE: To describe characteristics of men having sex with men (MSM) participating in the Omega Cohort, to describe HIV-positive participants at baseline interview, and to estimate HIV incidence. METHODS: The Omega Cohort is a study on the incidence and psychosocial determinants of HIV infection among MSM living in Montreal. MSM complete a questionnaire and are tested for HIV every six months. RESULTS: During the previous six months, 31% and 12% of 810 participants (mean age = 33 years) reported unprotected anal sex with regular and casual partners, respectively. Eight participants (0.98%) were HIV-infected at baseline. HIV incidence was 0.89 per 100 person-years (7/787 person-years) [95% confidence interval: 0.36-1.83]. CONCLUSION: A significant proportion of participants reported current risk behaviours. Despite this, HIV incidence is relatively low. It is important to target MSM who do not practice safe sex and to encourage those practicing safe sex to sustain these behaviours.     

乌鲁木齐市HIV阴性男男性行为者肛门HPV新发感染和感染清除研究

目的 了解乌鲁木齐市HIV阴性MSM肛门HPV新发感染和感染清除特征。方法 采用队列研究,通过乌鲁木齐市NGO组织于2016年4月11日至2021年11月30日以雪球抽样方式招募MSM 1269名,随访方式为每6个月1次,采集肛周脱落细胞进行HPV基因型检测,使用精确Poisson分布计算新发感染密度和感染清除密度,Cox比例风险模型分析新发感染、自然清除的影响因素。结果 将随访次数≥1 次的858名MSM纳入本次分析,中位年龄29.00（25.00,36.00） 月,中位随访时间26.28（10.57,48.82） 月,随访次数2.96（1.00,6.00）次。仅高危型、仅低危型和混合型新发感染密度分别是9.39/1000人月（95%CI:7.89~11.09）、4.45/1000人月（95%CI:3.52~5.54）、12.36/1000人月（95%CI:10.36~14.63）,清除密度分别为108.78/1000人月（95%CI:94.37~124.78）、96.76/1000人月（95%CI:78.19~118.41）和86.87/1000人月（95%CI:77.12~97.50）。HPV 6型和16型有相对更高的新发感染率和更低的清除率。HPV感染6个月清除率在30%~40%左右,90%左右的MSM在24个月会清除HPV。多变量分析中,接受性肛交（αHR=1.514,95%CI:1.025~2.811）、无业或失业（αHR=1.746,95%CI:1.085~2.811）增加仅高危型新发感染风险;≤24岁（αHR=2.227,95%CI:1.087~4.563）增加仅低危型新发感染风险;同性性伴数越多（αHR=1.051,95%CI:1.008~1.096）增加混合型新发感染风险;未在浴池寻找性伴（αHR=2.267,95%CI:1.036~4.961）更容易清除仅低危型;本科及以上（αHR=1.785,95%CI:1.234~2.582）、未发生商业性行为（αHR=1.967,95%CI:1.191~3.248）有利于HPV16/18型感染清除。结论 乌鲁木齐市MSM肛门HPV新发感染率较高,其中HPV 6型和16型较高的新发感染率和低清除率需要关注,虽然HPV感染24个月内自然清除率在90%左右,但仍存在一定比例的再发感染,有必要在年轻男性中接种HPV疫苗。     

不同性角色男男性行为人群的肛周人乳头瘤病毒感染及影响因素分析

目的 了解不同性角色男男性行为人群（men who have sex with men,MSM）的肛周人乳头瘤病毒（human papillomavirus,HPV）感染状况及其相关危险因素。方法 2016年3月~2017年4月于乌鲁木齐市采用滚雪球抽样法招募MSM 704名,通过问卷调查收集人口学与性行为特征数据,采集肛管内脱落细胞并使用37型HPV检测试剂盒进行分型鉴定。结果 MSM的肛周HPV既往感染率为50.4%,其中性角色"0"组与性角色"1"组的肛周HPV总感染率和低危型HPV的感染率不同,分别为54.6%、18.8%与45.6%、11.9%,差异均有统计学意义（均有P<0.05）。多因素Logistic回归分析显示,肛交有时使用安全套、近6个月同性商业性行为是性角色"0"组感染HPV的危险因素（均有P<0.05）;近6个月同性商业性行为是性角色"1"组感染HPV的危险因素（OR=3.04,95%CI:1.21~7.62,P=0.018）。结论 性角色"0"组与性角色"1"组之间肛周HPV感染率有差异,结合危险因素提倡MSM督促性伴使用安全套、避免商业性行为。     

Unprotected anal intercourse among HIV-positive men who have a steady male sex partner with negative or unknown HIV serostatus

OBJECTIVES: We sought to determine the prevalence and predictors of unprotected anal intercourse (UAI) among HIV-positive men who have a single steady male partner with negative or unknown HIV serostatus. METHODS: We analyzed behavioral surveillance data from HIV-positive men who have sex with men (MSM) interviewed in 12 states between 1995 and 2000. RESULTS: Of 970 HIV-positive MSM who had a single steady male sex partner with negative or unknown serostatus, 278 (29%) reported UAI during the previous year. In a subset of 674 men who were aware of their infection, 144 (21%) had UAI. Among the men who were aware of their infection, factors found to be predictive of UAI in multivariate modeling were heterosexual self-identification, crack cocaine use, no education beyond high school, and a partner with unknown serostatus. CONCLUSIONS: Even after learning of their infection, one fifth of HIV-positive MSM who had a single steady male partner with negative or unknown serostatus engaged in UAI, underscoring the need to expand HIV prevention interventions among these men.     

Systematic Review of Racial Disparities in Human Papillomavirus–Associated Anal Dysplasia and Anal Cancer Among Men Who Have Sex With Men

We systematically reviewed the literature on anal human papillomavirus (HPV) infection, dysplasia, and cancer among Black and White men who have sex with men (MSM) to determine if a racial disparity exists. We searched 4 databases for articles up to March 2014.Studies involving Black MSM are nearly absent from the literature. Of 25 eligible studies, 2 stratified by race and sexual behavior. Both reported an elevated rate of abnormal anal outcomes among Black MSM. White MSM had a 1.3 times lower prevalence of group-2 HPV (P < .01) and nearly 13% lower prevalence of anal dysplasia than did Black MSM.We were unable to determine factors driving the absence of Black MSM in this research and whether disparities in clinical care exist. Elevated rates of abnormal anal cytology among Black MSM in 2 studies indicate a need for future research in this population.Although it is relatively rare in the general US population, anal cancer and its precursors disproportionately affect men who have sex with men (MSM) and people living with HIV. Anal cancer rates have been found to be highest among HIV-infected MSM with an estimated anal cancer incidence of 131 per 100 000 for HIV-infected MSM, 46 per 100 000 for HIV-infected heterosexual men, and 30 per 100 000 in HIV-infected women.1 Furthermore, although the introduction of antiretroviral therapy has led to an increased life expectancy for HIV-infected individuals, a concomitant increase in anal cancer cases has occurred since 1996.2Anal intraepithelial neoplasia is the immediate precursor of anal cancer and presents as a low-grade squamous intraepithelial lesion or as a high-grade squamous intraepithelial lesion. Infection with human papillomavirus (HPV) is thought to cause the majority of anal intraepithelial neoplasia. Group-1 high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) are strongly carcinogenic; group-2 high-risk HPV types (HPV 26, 30, 34, 53, 66, 67, 68, 69, 70, 73, 82, 85, and 97) are weaker carcinogens and “probable” or “possible” causes of cancer.3 Although up to 90% of HPV infections are cleared within 2 years in the general population, HPV is much more likely to lead to anal cancer in HIV-infected individuals.4 Furthermore, rates of anal intraepithelial neoplasia have increased markedly among HIV-infected MSM.2Though MSM have been established as a group at high risk for anal cancer, no studies have been designed to study racial differences among MSM in anal HPV, dysplasia, and cancer. A focus on Black MSM is important in light of several factors that may have a differential impact on anal cancer risk in this population. First, oncogenic HPV subtypes have been found to be variably distributed across populations based upon race. For example, in 2 recent studies, Black women were found to have higher rates of HPV (such as 33, 35, 58, and 68) that are not included in the existing HPV vaccines.5,6 Second, transmission of HPV within sexual networks7 may propagate certain subtypes with variable oncogenic potential. Black communities, including Black MSM, are known to have more within-group sexual partners than Whites and other ethnic minorities who are more likely to have sexual mixing patterns involving individuals of other racial groups.7,8 Third, Black MSM have the highest HIV incidence rate compared with other MSM populations9 and thus will increasingly be at risk for anal cancer. Finally, marked disparities across access to care, prevention services, and health insurance10 put Black MSM at increased risk for preventable oncogenic anal HPV, dysplasia, and cancer.Previous reviews of anal HPV infection, dysplasia, and cancer have identified MSM as a high-risk group, highlighted an absence of young MSM from anal HPV studies, offered an explanation for the increase in anal cancer incidence, and explored cost-effectiveness of routine anal screening.11–14 We built upon previous work by comparing anal HPV infection, dysplasia, and cancer among MSM with data from past studies. We had 2 objectives with the systematic review. First, we aimed to determine if a racial disparity exists in anal HPV infection, dysplasia, and cancer screening. Second, we aimed to determine if a racial disparity exists in anal HPV infection, dysplasia, and cancer outcomes. We aimed to inform future research programs and the development of screening and care programs for Black MSM by identifying patterns in anal HPV infection, dysplasia, and cancer from the existing literature.     

Uptake and Predictors of Anal Cancer Screening in Men Who Have Sex With Men

Objectives. We investigated attitudes about and acceptance of anal Papanicolaou (Pap) screening among men who have sex with men (MSM).Methods. Free anal Pap screening (cytology) was offered to 1742 MSM in the Multicenter AIDS Cohort Study, who reported history of, attitudes about, and experience with screening. We explored predictors of declining screening with multivariate logistic regression.Results. A history of anal Pap screening was uncommon among non–HIV-infected MSM, but more common among HIV-infected MSM (10% vs 39%; P < .001). Most participants expressed moderate or strong interest in screening (86%), no anxiety about screening (66%), and a strong belief in the utility of screening (65%). Acceptance of screening during this study was high (85%) across all 4 US sites. Among those screened, most reported it was “not a big deal” or “not as bad as expected,” and 3% reported that it was “scary.” Declining to have screening was associated with Black race, anxiety about screening, and low interest, but not age or HIV status.Conclusions. This study demonstrated high acceptance of anal Pap screening among both HIV-infected and non–HIV-infected MSM across 4 US sites.In the past 3 decades, anal cancer incidence has increased 39% in women and 96% in men in the United States.1–3 In the general US population, anal cancer incidence remains higher among women than men (1.8 vs 1.4 cases per 100 000 annually), but the incidence is especially high among men who have sex with men (MSM; 35 per 100 000).4–6 Indeed, data suggest that anal cancer incidence among MSM may be similar to or higher than incidence of cervical cancer among US women before the introduction of cervical cytology screening in the mid-1950s.1,7–13 Incidence estimates for HIV-infected MSM are even higher and vary from 45.9 per 100 000 person-years14 in meta-analyses to 78.2 per 100 000 person-years15 for US AIDS Surveillance Epidemiology and End Results data.Human papillomavirus (HPV) infection is the major cause of anal cancer.4,14,16,17 Consistent with the increased anal cancer incidence among MSM, anal HPV prevalence and incidence are elevated among MSM compared with the general population.18,19 HIV-infected MSM have even higher anal HPV prevalence, compared with non–HIV-infected MSM (98% vs 57%).20,21 As effective antiretroviral therapy (ART, also referred to as HAART) helps HIV-infected individuals live longer, more may now develop anal cancer.6,22,23 On the basis of initial studies, it is unclear whether ART use reduces risk of anal intraepithelial neoplasia (AIN2/3, precancer)24 or anal cancer,25,26 although low CD4-cell count does appear to increase risk of anal cancer.27Recent research suggests that anal Papanicolaou (Pap) screening may have utility in preventing anal cancer9,28–30 and is a cost-effective screening method for anal cancer prevention among MSM.31,32 Like cervical dysplasia, anal dysplasia is slow-growing and treatable, and studies suggest that anal Pap tests can detect dysplasia with similar sensitivity and specificity to cervical Pap tests.33–35 On the basis of these data and the success of cervical Pap screening in reducing cervical cancer incidence, some have proposed routine anal Pap cytology (referred to as anal Pap screening hereafter) among MSM.9,36 However, these guidelines remain preliminary as researchers have not yet conducted a randomized trial to establish whether anal Pap screening reduces anal cancer deaths. Furthermore, recent studies have suggested that anal precancers (AIN2+) are relatively common among unscreened non–HIV-infected (∼4%) and HIV-infected (15%–30%) MSM, much higher than anal cancer rates, so other researchers have suggested that closer examination of the relative harms and benefits of treating all AIN 2/3 in MSM is first needed.24,35,37–40Despite the high incidence of anal cancer among MSM and recommendations, by some, for screening, MSM currently have low awareness of, access to, and use of anal Pap screening.41,42 Indeed, in our previous research, we observed a low reported prevalence of ever having anal Pap screening among MSM.43 We have expanded on these previous findings by examining acceptance of screening when offered for free. We also examined attitudes about anal Pap screening, experience with screening, and reasons for declining to have an anal Pap test.     

重庆地区男男性行为人群多性伴行为特征及影响因素

  目的   了解重庆地区艾滋病病毒(human immunodeficiency virus, HIV)阴性多性伴肛交(≥5人)男男性行为者(men who have sex with men, MSM)的人口学和性行为特征及其影响因素。   方法   从2018年6月至2019年6月, 招募重庆地区319名HIV阴性MSM, 收集其人口学特征、近半年内安全套使用率、是否感染性病、性角色、药物滥用史、是否服用过暴露后预防(post-exposure prophylaxis, PEP)药物、是否关注HIV知识和是否服用过暴露前预防(pre-exposure prophylaxis, PrEP)药物等信息。采用单因素和多因素Logistic回归分析模型分析MSM人群多性伴肛交的影响因素。   结果   319名HIV阴性MSM中, 34.5%(110/319)近6个月内性伴人数≥5人; 110名多性伴MSM中, 63.6%(70/110)年龄≤28岁, 75.4%(83/110)学历为大学本科或大专; 50名报告情感状况的MSM中, 72.0%(36/50)为单身。多因素Logistic回归分析模型分析显示, 服用过PEP药物和经常关注HIV知识是MSM多性伴肛交的主要影响因素。   结论   重庆地区HIV阴性MSM人群普遍存在多性伴肛交现象。应加大对MSM人群, 尤其是低龄MSM人群, HIV防治知识的宣教力度。在推广PrEP和PEP在MSM人群中的使用时, 应警惕其相关风险补偿。     

Men who have sex with men who do not access sexual health clinics nor disclose sexual orientation are unlikely to receive the HPV vaccine in the UK

BackgroundMen who have sex with men (MSM) are recommended the Human Papillomavirus (HPV) vaccination due to their higher risk of genital warts and anal cancer.PurposeTo examine HPV vaccine acceptability amongst MSM in the UK.MethodsUsing advertisements via Facebook, MSM were recruited to an online survey measuring motivations for HPV vaccination. Logistic regression was performed to identify predictors of HPV vaccine acceptability.ResultsOut of 1508 MSM (median age = 22, range: 14–63 years) only 19% knew about HPV. Overall, 55% of MSM were willing to ask for the HPV vaccine and 89% would accept it if offered by a healthcare professional (HCP). Access to sexual health clinics (SHCs) [OR = 1.82, 95% CI 1.29–2.89], the disclosure of sexual orientation to a HCP [OR = 2.02, CI 1.39–3.14] and HIV-positive status [OR = 1.96, CI 1.09–3.53] positively predicted HPV vaccine acceptability. After receiving information about HPV, perceptions of HPV risk [OR = 1.31, CI 1.05–1.63], HPV infection severity [OR = 1.89, CI 1.16–3.01), HPV vaccination benefits [OR = 1.61, CI 1.14–3.01], HPV vaccine effectiveness [OR = 1.54, CI 1.14–2.08], and the lack of perceived barriers to HPV vaccination [OR = 4.46, CI 2.95–6.73] were also associated with acceptability.ConclusionsAlthough nearly half of MSM would not actively pursue HPV vaccination, the vast majority would accept the vaccine if recommended by HCPs. In order to achieve optimal uptake, vaccine promotion campaigns should focus on MSM who do not access SHCs and those unwilling to disclose their sexual orientation.     

Oral and oropharyngeal high-risk HPV prevalence,HIV status,and risk behaviours in a cohort of South African men who have sex with men

Data lag is evident when observing studies focussing on human papillomavirus (HPV) prevalence in the head and neck of men who have sex with men (MSM) in Southern Africa. Sexual behaviours other than anal intercourse, and associated factors are similarly underreported. HPV vaccination has not yet commenced for this population group. One hundred and ninety-nine MSM were enrolled in this study. Participants completed a questionnaire followed by a clinical oral examination, and a rinse-and-gargle specimen in Thinprep^® vials containing Preservcyt^® solution was collected. Detection and genotyping for high-risk HPV were done by an automated system (Abbott^® m2000sp). Six percent of MSM in this cohort had high-risk HPV present in the mouth/oropharynx. This cohort averages 29 years of age, more than half were unemployed (53.3%), and 66.8% were human immunodeficiency virus (HIV) seropositive. The most common sexual practice was anal sex (69.4%) followed by oral sex (28.6%), and by rimming (9.6%). A significant association between oral insertive sex and oral/oropharyngeal HPV status was demonstrated (p = 0.0038; phi coefficient = 0.20). An incidental but significant association between rimming and HIV status was found (p = 0.0046; phi coefficient = 0.19), and HIV seropositive participants had higher oral/oropharyngeal HPV presence. The HPV prevalence of 6% reported in this study is in alignment with global reports. The prevalence of oral/oropharyngeal HPV in this MSM cohort was influenced by sexual practices. MSM participants who practiced rimming appear to be at higher risk of HIV acquisition. Given the transmission routes of HPV in this vulnerable population, vaccination must be urgently studied as an intervention for prevention.     

Anorectal lymphogranuloma venereum in a Melbourne man

We report the first case of anorectal lymphogranuloma venereum (LGV) in a man who has sex with men (MSM) in Australia in the setting of the recent emergence of LGV among MSM in Europe and the USA. A 33-year-old man presented with a 2 month history of mild external anal discomfort. He gave a history of unprotected receptive and insertive anal intercourse with one partner in Europe during the preceding 6 months. No symptoms suggested proctitis and examination revealed two small anal fissures. An anal swab was positive for Chlamydia trachomatis; investigation for other STIs including HIV were negative. On review 6 days later, he was investigated and treated presumptively for LGV. The LGV diagnosis was confirmed by identifying the L2 serovar of C. trachomatis using a genotype test on the original anal specimen. This case is in keeping with the more recent reports of LGV from Europe, and has demonstrated the need for a high index of suspicion for asymptomatic or minimally symptomatic anorectal LGV.     

北京市男男性行为者HIV和梅毒螺旋体血清抗体阳转率及影响因素

目的 了解北京市男男性行为者(MSM)的HIV和梅毒螺旋体血清抗体阳转情况及其影响因素. 方法 在北京市以社区为基础招募HIV阴性的MSM共525名,以一对一的方式进行问卷调查,收集人口学和行为学情况资料,在第6、12个月进行随访,并采集血样进行HIV和梅毒螺旋体抗体检测,初筛均采用ELISA法,确证分别采用蛋白印迹(WB)和凝集法. 结果 基线共调查550名,HIV和梅毒螺旋体血清抗体阳性率分别为4.5%(25/550)和29.3%(161/550),HIV血清抗体阴性队列525名,随访12个月,队列保持率为87.0%(457/525),HIV和梅毒螺旋体血清抗体阳转率分别为3.37/100人年和9.32/100人年.近3个月同性性行为后冲洗直肠者阳转率为7.11/100人年,未冲洗者为0.76/100人年,冲洗与HIV血清抗体阳转相关(HR=9.23,95%CI=2.08～40.88).近3个月在公园、公厕或浴池寻找男性性伴者阳转率为41.77/100人年,无该行为者阳转率为7.97/100人年;近3个月同性性行为后冲洗直肠者阳转率为16.17/100人年,无该行为者阳转率为4.92/100人年;近3个月在公园、公厕或浴池寻找男性性伴(HR=4.67,95%CI=1.77～12.34)和近3个月同性性行为后冲洗直肠(HR=3.09,95%CI=1.40～6.83)与梅毒螺旋体血清抗体阳转相关. 结论 北京市MSM的HIV和梅毒螺旋体血清抗体阳转情况十分严重,主要影响因素为同性性行为后冲洗直肠、到公园等场所寻找男性性伴.

Abstract：

Objective To study the incidence and risk factors of HIV and syphilis seroconversion among men who have sex with men(MSM) in Beijing. Methods A total of 550 MSM were recruited on the basis of community and followed up after 6 and 12 months in Beijing.Each subject was investigated by only one investigator at one time to collect information on demographics and behaviors.Blood samples were collected to test HIV and syphilis seroconversion.ELISA was used for screening test,west blotting(WB) and Particle agglutination were used for confirmatory test. Results A total of 550 MSM investigated,among which 4.5% (25/550) were HIV-positive and 29.3% (161/550) were syphilis-positive.For 525 HIVnegative MSM,87.0% (457/525) retained during the 12-month investigation.Seroincidences for HIV and syphilis were 3.37/100 person-years (95% CI = 1.66-5.08) and 9.32/100 person-years (95% CI =5.87-12.77) respectively.HIV seroconversions for those who performed and did not perform rectal douching after homosexual anal intercourse in the past 3 months were 7.11/100 and 0.76/100 person-years respectively.Multivariate Cox regression analysis revealed that rectal douching after homosexual anal intercourse in the past 3 months(HR=9.23,95%CI =2.08-40.88) was significantly associated with HIV seroconversion.Syphilis seroconversions for those who met male sex partners in parks,public washrooms or bathhouses in the past 3 months were 41.77/100 and 7.97/100 person-years respectively.Syphilis seroconversions for those who performed and did not perform rectal douching after homosexual anal intercourse in the past 3 months were 16.17/100 and 4.92/100 person-years respectively.In the past 3 months,meeting male sex partners in parks,public washrooms or bathhouses (HR=4.67,95% CI = 1.77-12.34) and performing rectal douching after homosexual anal intercourse (HR = 3.09,95% CI=1.40-6.83) were significantly associated with syphilis seroconversion. Conclusion The seroconversions of HIV and syphilis during the follow-up visits in this MSM cohort study in Beijing were very serious,and that the associated factors for seroconversions were rectal douching after homosexual anal intercourse and meeting male sex partners in parks,public washrooms or bathhouses.     

Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia

We examined the long-term clinical and economic benefits of quadrivalent human papillomavirus (qHPV) vaccine as a secondary/adjunct prevention strategy in the prevention of recurrent high-grade intraepithelial neoplasia (HGAIN) in HIV-negative men who have sex with men (MSM) and are 27 years or older. We constructed a Markov model to evaluate the clinical effectiveness and cost-effectiveness of two strategies: (1) no qHPV vaccine after treatment for HGAIN versus (2) qHPV vaccine after treatment for HGAIN. Model parameters, including natural history of anal cancer, vaccine efficacy measured in terms of hazard ratio (HR) (decrease in the risk of recurrent HGAIN), HGAIN treatment efficacy, utilities, and costs, were obtained from the literature. The outcomes were measured in terms of lifetime risk of anal cancer, lifetime cost, quality-adjusted life years, and incremental cost-effectiveness ratios (ICERs). Sensitivity analysis was conducted on all model parameters. We found that vaccinating HIV-negative MSM reduced the lifetime risk of anal cancer by 60.77% at an ICER of US$87,240 per quality-adjusted life-year. The results were highly sensitive to vaccine efficacy, transition of HGAIN to anal cancer, cost of treatment for HGAIN, vaccine degree of protection over time, and the vaccine duration of protection and less sensitive to HPV clearance, cost of qHPV vaccine, and the transitions from normal to low-grade anal intraepithelial neoplasia (LGAIN) and normal to HGAIN. With an HR of 0.3, the ICER was well below a $50,000 willingness-to-pay threshold; with an HR of 0.5, the ICER was still below a threshold of $100,000. The most critical disease-related factor influencing the cost-effectiveness was the progression of HGAIN to anal cancer. At an annual transition probability below 0.001, the ICER was below $50,000. Vaccinating HIV-negative MSM treated for HGAIN decreases the lifetime risk of anal cancer and is likely to be a cost-effective intervention.     

Ambivalent tales of HIV disclosure in San Francisco

In light of rising levels of unprotected anal intercourse (UAI) among men who have sex with men (MSM) in San Francisco, we sought to understand disclosure practices, the calculus of risk and attitudes about HIV seroconversion. In 2000, 150 MSM participated in interviews pivoting around a detailed narrative of a recent incident of UAI. In order to understand the relationship between individual and community norms, we analyzed the narratives as accounts situated within the respondents' experience of the HIV epidemic and the gay community in San Francisco. In justifying their risky sexual practices, MSM cited a community-wide shift toward non-disclosure and barebacking since the advent of highly active anti-retroviral therapy (HAART). Fearing rejection by HIV-positive partners who refuse to use condoms, HIV-negative men saw little advantage in disclosing to casual partners whom they perceived as overwhelmingly HIV-positive. By contrast, HIV-positive men appeared eager to disclose their positive status to release themselves from responsibility for transmission and facilitate "bareback" or unprotected sex. Disavowal of individual responsibility for safer sex in deference to community norms may contribute to the recent spiraling of risk behavior and HIV incidence. Implications for prevention policy are discussed.